Department of Anesthesiology and Pain Medicine, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea
Copyright © 2014 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| System | Effect |
|---|---|
| Cardiovascular | Increased myocardial oxygen demand |
| Respiratory | Hyperventilation, lowered residual capacity, ventilator dyssynchrony, atelectasis, hypoxia |
| Gastrointestinal | Decreased motility |
| Renal | Activation of the renin-angiotensin-aldosterone system |
| Endocrine | Hyperglycemia and hypotension due to hormonal imbalance, especially cortisol and insulin, increased catabolism |
| Hematological | Hypercoagulability and platelet dysfunction, increased risk of thromboembolic disease and gastrointestinal bleeding |
| Psychological | Depression, fatigue, psychosis, anxiety, sleep disturbance and serotonergic imbalance |
| Immune | Suppressed immunomodulation through cytokine elaboration and leukocyte dysfunction (especially NK cells) |
| Opiates | Metabolism | Onset/duration | Dose (bolus/maintenance) | Advantages | Disadvantages |
|---|---|---|---|---|---|
| Fentanyl | N-dealkylation | 1–2 min/2–4 hr (longer in liver failure) | 25–50 μg IV push/12.5–200 μg/hr continuous infusion | Less hypotension than with morphine | Accumulates with hepatic dysfunction |
| Hydromorphone | Hepatic | 5–15 min/2–3 hr (longer in liver failure) | 1–4 mg IV push/0.25–50 mg/hr (no real maximum dose) | Can be used in patients tolerant to morphine or fentanyl | Accumulates with hepatic/renal dysfunction |
| Morphine | Hepatic/renal (active metabolite) | 5–10 min/3–4 hr (longer in liver failure and ESRD) | 2–4 mg IV push/0.5–49 mg/hr | May be preferred in patients with tachyphylaxis to fentanyl | Accumulates with hepatic/renal dysfunction histamine release |
| Remifentanil | Plasma esterase | 1–3 min/3–10 min | 1 μg/kg over 1 min IV push/0.6–15 μg/kg/hr (use IBW if more than 30% over IBW) | No accumulation in hepatic/renal dysfunction | Can cause bradycardia and hypotension Use IBW if body weight > 130% IBW |
| Block | Indications | Contraindications | Practical problems | Dose suggestions (bolus/continuous) |
|---|---|---|---|---|
| Interscalene | Shoulder/arm pain | Untreated contralateral pneumothorax Dependence on diaphragmatic breathing Contralateral vocal cord palsy Reduced functional residual capacity |
Horner syndrome may obscure neurologic assessment Block of ipsilateral phrenic nerve Close proximity to tracheostomy and jugular vein catheter sites |
10 ml of 0.25% bupivacaine or 0.2% ropivacaine every 8–12 hr and on demand/0.125% bupivacaine or 0.1–0.2% ropivacaine at 5 ml/hr |
| Axillary | Arm/hand | Arm positioning Not suitable for catheter positioning |
Same with infraclavicular | |
| Infraclavicular/supraclavicular | Arm/hand pain | Severe coagulopathy Untreated contralateral pneumothorax |
Pneumothorax Interference with subclavian central venous catheters |
10–20 ml of 0.25% bupivacaine or 0.2% ropivacaine every 8312 hr and on demand/0.125% bupivacaine or 0.1–0.2% ropivacaine at 5–10 ml/hr |
| Paravertebral (cervical) | Shoulder/elbow/wrist | Horner syndrome may obscure neurologic assessment Block of ipsilateral phrenic nerve Patient positioning |
Same with interscalene | |
| Paravertebral (thoracic/lumbar) | Unilateral chest or abdomen restricted to few dermatomes | Severe coagulopathy Untreated contralateral pneumothorax |
Patient positioning | Same with infraclavicular |
| Femoral and/or sciatic | Unilateral lower extremity | Severe coagulopathy | Patient positioning Interference of femoral nerve catheters with femoral catheters |
Same with infraclavicular |
| Pain can be relieved easily by simple methods such as repositioning or fixation of limb or body |
| Have to treat after identification and adjustment of other causes of pain such as fixation, adjustment (e.g., withdrawal of endotracheal tube), or removal of devices |
| Anatomically localized pain in a specific region such as postoperative or procedural pain is amenable to regional analgesic techniques |
| Patient’s level of consciousness has to be enough to evaluate the effectiveness of regional analgesia |
| Regional analgesic techniques are contraindicated in the following conditions: patient refusal, local infection at the needle insertion site, preexisting neuropathy, local anesthetic allergies, severe bleeding tendency |
| Risks can be reduced during the regional analgesia through use of ultrasound, tunneled catheters, correction of severe bleeding tendency |
NK cells: natural killer cells.
ESRD: end stage renal disease; IBW: ideal body weight.
All the above-mentioned peripheral nerve blocks are contraindicated in the following conditions: patient refusal, local infection at the needle insertion site, preexisting neuropathy, local anesthetic allergies. ICU: intensive care unit.